Publications by authors named "Zehu Sheng"
Background: Recent studies have demonstrated that β2 microglobulin is an important factor in β-amyloid (Aβ) neurotoxicity and a potential target for the treatment of AD. Although β2 microglobulin, soluble triggering receptor expressed on myeloid cells 2 (sTREM2) and Glial fbrillary acidic protein (GFAP) are involved in the neuroinflammatory response to promote the development of AD, their relationship in AD pathology remains to be studied.
Method: A total of a11 participants with cerebrospinal fuid (CSF) and Plasma β2 microglobulin, CSF sTREM2, GFAP, and AD biomarkers(Aβ; phosphorylated-tau, P-tau; and total tau, T-tau) were included from the Alzheimer's disease Neuroimaging Initiative (ADNI).
Background: Bridging integrator 1 (BIN1), one of the most strongly associated gene with Alzheimer's disease (AD). It has been reported to play a role in the pathological processes of AD; however, the exact mechanism has not yet been completely found.
Method: Alzheimer's Disease Neuroimaging Initiative (ADNI, N = 495) was the discovery cohort, and the Chinese Alzheimer's Biomarker and LifestylE (CABLE, N = 619) study was used to replicate the results.
Background: Cerebrospinal fluid (CSF) β2-microglobulin (β2M) has been demonstrated as an important factor in β-amyloid (Aβ) neurotoxicity and a potential target for Alzheimer's disease (AD). However, more investigation is required to ascertain the relationship between β2M and glial activities in AD pathogenesis.
Methods: In this study, 211 participants from the Alzheimer's disease Neuroimaging Initiative (ADNI) with CSF and Plasma β2M, CSF glial fibrillary acidic protein (GFAP), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), Aβ, phosphorylated-tau (P-tau) and total tau (T-tau) were divided into four groups, stage 0, 1, 2, and suspected non-AD pathology (SNAP) based on the National Institute on Aging- Alzheimer's Association (NIA-AA) criteria.
Background: The occurrence of Alzheimer's disease (AD) can be partially prevented through healthy lifestyles, but the mechanisms associated with AD pathology are unclear.
Objective: To explore associations among healthy lifestyle characteristics (HLCs), cerebrospinal fluid (CSF) soluble TREM2 (sTREM2), and AD biomarkers.
Methods: From the Chinese Alzheimer's Biomarker and LifestylE (CABLE) study, 924 cognitively normal participants were enrolled in this cross-sectional analysis.
Background: The correlation between Alzheimer's disease (AD) and the glucose-triglyceride (TyG) index remains undetermined.
Objective: This study aimed to investigate the relationship between the TyG index and AD, as well as the relationship between the TyG index and cerebrospinal fluid (CSF) AD biomarkers and cognition.
Methods: Six hundred twenty-eight non-dementia participants were included.
Article Synopsis
- The study investigates how variations in the BIN1 gene are linked to neuroinflammation and Alzheimer's disease (AD) pathology, focusing on two specific genetic polymorphisms: rs7561528 and rs744373.
- Using data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Chinese Alzheimer's Biomarker and Lifestyle (CABLE) study, researchers found a significant relationship between BIN1 loci and levels of key Alzheimer's biomarkers in cerebrospinal fluid (CSF), particularly phosphorylated-tau (P-tau), total-tau (T-tau), and microglial activation marker sTREM2.
- The findings suggest that the association between BIN1 loci and tau pathology is
Background: The relationship between Alzheimer's disease (AD)-related pathology and cognition was not exactly consistent.
Objective: To explore whether the association between AD pathology and cognition can be moderated by frailty.
Methods: We included 1711 participants from the Alzheimer's Disease Neuroimaging Initiative database.
The relationship between the triglyceride glucose-body mass index (TyG-BMI) index and Alzheimer's disease (AD) pathology, cognition, and brain structure remains unclear. This study aimed to investigate these associations, focusing on cerebrospinal fluid (CSF) biomarkers, cognitive measures, and brain imaging data. Eight hundred and fifty-five non-demented participants were included.
View Article and Find Full Text PDFBackground: Frailty is a vulnerability state increasing the risk of many adverse health outcomes, but little is known about the effects of frailty on neuropsychiatric health.
Objective: To explore the associations between frailty and the risk of neuropsychiatric symptoms (NPSs) in Alzheimer's disease (AD), especially in its different clinical stages.
Methods: We included 2,155 individuals assessed using modified frailty index-11 (mFI-11), Neuropsychiatric Inventory (NPI) and Neuropsychiatric Inventory Questionnaire (NPI-Q) in the Alzheimer's Disease Neuroimaging Initiative (ADNI).
Background: Clusterin, a glycoprotein implicated in Alzheimer's disease (AD), remains unclear. The objective of this study was to analyze the effect of cerebrospinal fluid (CSF) clusterin in relation to AD biomarkers using a longitudinal cohort of non-demented individuals.
Methods: We gathered a sample comprising 86 individuals under cognition normal (CN) and 134 patients diagnosed with MCI via the Alzheimer's Disease Neuroimaging Initiative (ADNI) database.
Article Synopsis
- The study explores the use of neurofilament light chain protein (NfL) levels in cerebrospinal fluid (CSF) as a biomarker for monitoring cognitive decline in Parkinson's disease (PD) and its dementia form (PD-D).
- Researchers analyzed data from 259 participants, focusing on how CSF NfL concentrations correlate with cognitive impairment and decline over time.
- They found that higher baseline and increasing levels of CSF NfL significantly predicted cognitive decline in patients, especially among certain demographics like older males and those with less education.
Background: APOE ɛ4 genotype was correlated with exacerbation of pathology and higher risk of dementia in Parkinson's disease (PD). Meanwhile, the differential influence of APOE ɛ4 on cognition in young and old individuals interpreted as antagonistic pleiotropy.
Objective: To examine whether the effect of APOE ɛ4 on cognitive progression in de novo PD is age dependent.
Background: The relationship between serum uric acid (UA) and Alzheimer's disease (AD) risk still remained ambiguous despite extensive attempts.
Objective: Via the two-sample Mendelian randomization (MR) design, we aimed to examine the bidirectional causal relationships of serum UA, gout, and the risk of AD.
Methods: Genetic variants of UA, gout, and AD were extracted from published genome-wide association summary statistics.